FluroTech Ltd
FluroTech Ltd. focuses on the commercialization of fluorescence spectroscopy technology to test for COVID-19. FluroTech Ltd. is based in Calgary, Canada.
FluroTech Ltd (FLURF) - Net Assets
Latest net assets as of September 2024: $-119.58K USD
Based on the latest financial reports, FluroTech Ltd (FLURF) has net assets worth $-119.58K USD as of September 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($282.20K) and total liabilities ($401.78K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-119.58K |
| % of Total Assets | -42.38% |
| Annual Growth Rate | N/A |
| 5-Year Change | -105.93% |
| 10-Year Change | N/A |
| Growth Volatility | 1624.08 |
FluroTech Ltd - Net Assets Trend (2016–2023)
This chart illustrates how FluroTech Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for FluroTech Ltd (2016–2023)
The table below shows the annual net assets of FluroTech Ltd from 2016 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-180.35K | -107.60% |
| 2022-12-31 | $-86.88K | -111.15% |
| 2021-12-31 | $779.31K | +66.43% |
| 2020-12-31 | $468.24K | -84.61% |
| 2019-12-31 | $3.04 Million | -46.59% |
| 2018-12-31 | $5.70 Million | +4315.01% |
| 2017-12-31 | $129.01K | -25.48% |
| 2016-12-31 | $173.12K | -- |
Equity Component Analysis
This analysis shows how different components contribute to FluroTech Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 2480627000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $25.08 Million | % |
| Total Equity | $-180.35K | 100.00% |
FluroTech Ltd Competitors by Market Cap
The table below lists competitors of FluroTech Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
FIDIA EO 1
F:FIC
|
$31.88K |
|
ERCROS (CRS1.SG)
STU:CRS1
|
$31.88K |
|
Golden Metal Resources PLC
LSE:GMET
|
$31.92K |
|
Turn Therapeutics Inc. Common Stock
NASDAQ:TTRX
|
$31.93K |
|
Macquarie Infrastructure Holdings LLC
STU:14M
|
$31.82K |
|
DUET Acquisition Corp. Warrant
NASDAQ:DUETW
|
$31.82K |
|
Tvardi Therapeutics, Inc.
NASDAQ:TVRD
|
$31.80K |
|
PRNR3F
SA:PRNR3F
|
$31.73K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FluroTech Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from -86,875 to -180,349, a change of -93,474.
- Net loss of 98,888 reduced equity.
- Other factors increased equity by 5,414.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-98.89K | -54.83% |
| Other Changes | $5.41K | +3.0% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares FluroTech Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $0.00 | $0.00 | x |
| 2017-12-31 | $0.02 | $0.00 | x |
| 2018-12-31 | $0.11 | $0.00 | x |
| 2019-12-31 | $0.06 | $0.00 | x |
| 2020-12-31 | $0.01 | $0.00 | x |
| 2021-12-31 | $0.01 | $0.00 | x |
| 2022-12-31 | $0.00 | $0.00 | x |
| 2023-12-31 | $-0.02 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FluroTech Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-278.15%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -22.02% | 0.00% | 0.00x | 1.13x | $-55.43K |
| 2017 | -34.19% | 0.00% | 0.00x | 1.16x | $-57.01K |
| 2018 | -90.02% | 0.00% | 0.00x | 1.09x | $-5.70 Million |
| 2019 | -142.92% | -1735.24% | 0.07x | 1.19x | $-4.65 Million |
| 2020 | -571.15% | -882.16% | 0.40x | 1.62x | $-2.72 Million |
| 2021 | -1364.93% | 0.00% | 0.00x | 1.61x | $-10.71 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.11 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-80.85K |
Industry Comparison
This section compares FluroTech Ltd's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $498,972,584
- Average return on equity (ROE) among peers: -54.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FluroTech Ltd (FLURF) | $-119.58K | -22.02% | N/A | $31.85K |
| Advanced Biomedical Technologies Inc (ABMT) | $-2.23 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $187.53 Billion |
| Acarix AB (publ) (ACIXF) | $51.88 Million | -150.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $3.82 Million |
| Adm Tronics Unltd (ADMT) | $644.00K | 0.00% | 0.66x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $6.03 Million | -94.15% | 0.22x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $75.02 Million | -52.81% | 0.78x | $732.88K |
| Adapthealth Corp (AHCO) | $24.31K | -2.84% | 11.78x | $916.00 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $9.37 Million | 23.33% | 0.30x | $8.41 Million |